TITLE

TOP 20 PHARMA: #15 BAYER SCHERING

PUB. DATE
July 2009
SOURCE
Contract Pharma;2009, Vol. 11 Issue 6, p84
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article profiles Bayer Schering Pharma AG, the rank 15 among the top 20 pharmaceutical companies based in Leverkusen, Germany. It notes that it was founded in 1971 and handles 108,600 employees. It mentions its plan to strengthen its research and development initiative in 2009 through its 4 billion U.S. dollars budget. In addition, it has handed worldwide marketing and distribution rights to its oncology drugs Fludara and Leukine. Information about its drugs and affiliations is also offered.
ACCESSION #
44147475

 

Related Articles

  • Bayer Schering Pharma to Open R & D Center in Beijing.  // China Chemical Reporter;3/6/2009, Vol. 20 Issue 7, p8 

    The article reports on the move of Bayer Schering Pharma AG, a division of Bayer HealthCare, to invest US$129 million in a new global research and development (R&D) center in Beijing, China. It states that China will be the third country to host a R&D center for Bayer Schering Pharma besides...

  • COMPANY SPOTLIGHT -- Bayer Schering Pharma.  // PharmaWatch: Cancer;Jan2010, Vol. 9 Issue 1, p25 

    The article offers information on business operations of the pharmaceutical company Bayer Schering Pharma AG. It reports Bayer's recent deal with Micromet Inc. for the development of a new antibody called BiTE for tumor treatment, and gives an overview of its foundation, business growth,...

  • Schering renamed.  // European Pharmaceutical Executive;Feb/Mar2007, p10 

    The article reports on Germany-based Schering AG's decision to change its name to Bayer Schering Pharma AG. The necessary entry in the commercial register took effect on December 29, 2006. The article also reports that the new logo has been mounted on Bayer Schering Pharma's headquarters in...

  • Schering and Bayer seal drug ownership agreement. Chynoweth, Emma // ICIS Chemical Business;4/2/2007, Vol. 2 Issue 60, p33 

    This article reports that Bayer Schering Pharma and Novartis have settled a dispute over U.S. production of the interferon-based multiple sclerosis treatment Betaseron, sold in the U.S. as Betaferon. The deal sees Bayer Schering Pharma acquiring most of Novartis' Emeryville, California, site,...

  • European pharma consolidation generates quality spinoffs. Sheridan, Cormac // Nature Biotechnology;Dec2006, Vol. 24 Issue 12, p1458 

    The article focuses on the consolidation and acquisition of European pharmaceutical companies. The article discuses that Berlin based Schering company and two German companies are acquired by Bayer Healthcare, Germany, to establish Bayer-Schering Pharma. And the establishment will concentrate on...

  • COMPANY SPOTLIGHT -- Bayer Schering.  // PharmaWatch: CNS;Nov2010, Vol. 9 Issue 11, p19 

    The article features Bayer Schering Pharma AG. It relates that the pharmaceutical company is a research-based company which engaged in the manufacturing, developing, and marketing of pharmaceutical products. It says that the company focuses in four businesses including diagnostic imaging,...

  • BREAKING NEWS.  // Pharmaceutical Technology;Feb2007, Vol. 31 Issue 2, p20 

    The article presents a summary of news events from December 2006 to January 2007 in the pharmaceutical industry, which were published in the "Weekly Electronic Newsletter of Pharmaceutical Technology." In Berlin and Leverkusen, Germany, Bayer Schering Pharma was launched as a start up company...

  • EPIX Regains Vasovist Rights.  // BioWorld Today;9/5/2008, Vol. 19 Issue 173, p3 

    The article reports on the plan of EPIX Pharmaceuticals Inc. to regain full worldwide commercial rights for the imaging product Vasovist from Bayer Schering Pharma in 2008. EPIX hopes to have U.S. approval of the product by the end of the year. The firm had been awaiting word from Bayer on...

  • Lymphoma Update.  // PharmaWatch: Cancer;Jun2008, Vol. 7 Issue 6, p4 

    The article offers updates on the results of lymphoma trials by several pharmaceutical companies in Europe. Medarex Inc. announced data from its Phase I/II trial suggesting the dosage escalation of lymphoma antibodies to patients. Antisoma PLC revealed the effectiveness of its anti-nucleolin...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics